A literature review by researchers at the Abramson Cancer Center has identified a potential use of the cell cycle inhibitor palbociclib in a variety of cancers.
Earlier this year, the FDA approved palbociclib as frontline treatment for postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer. An inhibitor of the cyclin-dependent kinase (CDK) 4/6 proteins, palbociclib halts the cell division cycle and prevent proliferation of the cancer cells. Now, a new report has identified potential use of this cell cycle inhibitor in a variety of other cancers.
Experts at the Abramson Cancer Center, University of Pennsylvania, conducted a literature review of preclinical and translational data and early- and late-phase clinical trials that evaluated palbociclib in diverse tumor types, published till March 1, 2015. Lead study author Amy S. Clarke, MD, MSCE, lead author on the paper believes, “All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process therefore has potentially broad applicability.”
The following were the key findings of the review:
Senior study author Peter J. O'Dwyer, MD, said, “This drug has minor effects on normal cells other than neutrophils (white blood cells. In tumors, it can cause shrinkage, or more commonly, arrest of growth. As we discover new functions for the CDK4/6 target of this medicine, we are likely to use it in combinations to make other anti-cancer agents work better.” Additionally, recent findings that palbociclib has targets beyond the cell cycle can expand could significantly expand its therapeutic role, O’Dwyer believes.
The safety records of palbociclib in breast cancer studies are quite encouraging, with the primary adverse effect being reversible neutropenia with a once-daily dosing. This can be overcome with temporary discontinuation of the drug and reintroducing it at a lower dose. Other side effects of palbociclib include fatigue, nausea, diarrhea, constipation, and rash.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More